Follicular Lymphoma

Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.

Last year, the anticancer drug Tazverik (tazemetostat) received approval for use in the treatment of 2 malignancies.

With a demanding career and 3 small children, Pam Neff had to make some difficult decisions during her treatment for an aggressive blood cancer.

For Erika Brooks, it took some time to adjust to what it means to have an incurable cancer. She says, “at first, I kept thinking it was a death sentence.” Eventually, she came to see her cancer in a different light.

Several new treatment options were approved by the FDA for patients with follicular lymphoma.

Here is an outline of what to expect when follicular lymphoma returns.